Akeso logs Phase III success in second tumour type for ivonescimab
Ivonescimab is currently in global clinical trials for various solid tumour indications, while being under US regulatory review for NSCLC.
26 August 2026
26 August 2026
Ivonescimab is currently in global clinical trials for various solid tumour indications, while being under US regulatory review for NSCLC.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.